What does issuance cost of the2025pipe financing mean?

The specific transaction costs incurred to execute a PIPE financing round, including underwriting and professional service fees. Monitoring this metric allows for the evaluation of the cost-effectiveness of the company's specific financing strategies.

Oruka Therapeutics, Inc. ORKA Issuance Cost Of The2025PIPE Financing

Issuance Cost Of The2025PIPE Financing at other companies

Navitas Semiconductor CorporationNVTS

$1.11M—

MPLXMPLX

$15M-21.1%

Option Care Health, Inc.OPCH

$2.04M—

Starwood Property TrustSTWD

$12.6M-17.6%

Energy TransferET

$48M-5.9%

Bloom EnergyBE

$806K—

Other financials

Income statement

See full

Revenue-—

Operating income-$36.4M-45.2%

Net income-$31.8M-51.5%

EPS (diluted)-$0.46+93.4%

Balance sheet

See full

Cash & equivalents$49.5M-40.7%

Total debt$1.8M+90.8%

Total equity$486.7M+33.4%

Total assets$504.5M+33.8%

Cash flow

See full

Operating cash flow-$23.6M-13.0%

CapEx$73.0K+462%

Free cash flow-$23.7M-13.3%

Valuation

See full

Market cap$5.03B+533%

Returns & leverage

See full

Return on equity-27.3%-11.1pp

Debt / equity0×0.0×

Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept orka:IssuanceCostOfThe2025PIPEFinancing.

The official record: Oruka Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s issuance cost of the2025pipe financing.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s issuance cost of the2025pipe financing?: Oruka Therapeutics, Inc. (ORKA) reported issuance cost of the2025pipe financing of -$2.59M in Q4 2025.
What does issuance cost of the2025pipe financing mean?: The specific transaction costs incurred to execute a PIPE financing round, including underwriting and professional service fees. Monitoring this metric allows for the evaluation of the cost-effectiveness of the company's specific financing strategies.